US 11,786,552 B2
Therapeutic compositions and applications that comprise nucleic acids and adoptively transferred immune cell
Yafei Hou, Mountain View, CA (US); Fang Hu, Hangzhou (CN); Jipo Sheng, Hangzhou (CN); Xiankui Tan, Hangzhou (CN); and Can Chen, Hangzhou (CN)
Assigned to HANGZHOU CONVERO CO., LTD., Hangzhou (CN); and Yafei Hou, Mountain View, CA (US)
Filed by HANGZHOU CONVERD CO., LTD., Zhejiang (CN); and Yafei Hou, Mountain View, CA (US)
Filed on Feb. 24, 2020, as Appl. No. 16/798,465.
Application 16/798,465 is a continuation in part of application No. PCT/CN2019/102584, filed on Aug. 26, 2019.
Claims priority of application No. 201810972316.5 (CN), filed on Aug. 24, 2018.
Prior Publication US 2020/0289567 A1, Sep. 17, 2020
Int. Cl. A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61K 35/768 (2015.01); A61K 38/28 (2006.01); A61K 38/17 (2006.01); A61P 35/00 (2006.01); C07K 14/725 (2006.01); C07K 14/74 (2006.01); C12N 7/00 (2006.01)
CPC A61K 35/17 (2013.01) [A61K 35/768 (2013.01); A61K 38/1774 (2013.01); A61K 38/28 (2013.01); A61K 39/0011 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70539 (2013.01); C12N 7/00 (2013.01)] 13 Claims
 
1. A therapeutic agent for the treatment of tumors and/or cancers of a subject, comprising:
(a) a first pharmaceutical composition comprising a first active ingredient in a first druggable vehicle, wherein the first active ingredient comprises a nucleic acid encoding a labelling polypeptide;
(b) a second pharmaceutical composition comprising a second active ingredient in a second druggable vehicle, wherein the second active ingredient comprises immune cells purified from peripheral blood or from tumor tissue and are cultured in vitro;
wherein the nucleic acid when administered to the patient as part of the first pharmaceutical composition causes the tumor cells and/or cancer cells of the patient to express immunogens that can elicit an immune response of the immune cells;
wherein the labelling polypeptide comprises three identical antigenic epitope peptides derived from a tumor-associated antigen of NY-ESO-1 157-165 (SEQ ID NO:2), and the immune cells comprise TCR-modified T cells that can specifically recognize and bind to the labelling polypeptide; and
wherein the first active ingredient is a recombinant oncolytic adenovirus capable of selectively replicating in tumor cells.